12.8  1.3 (11.3%)		03-13 16:00
Open: 13.52 High: 14.79 Volume: 1,095,505		Pre. Close: 11.5 Low: 12.57 Market Cap: 121(M)

Short term
Mid term
Targets	6-month :	17.27	1-year :	20.17
Resists	First :	14.78	Second :	17.27
Pivot price	11.66
Supports	First :	12.17	Second :	10.56
MAs	MA(5) :	11.96	MA(20) :	11.58
	MA(100) :	14.36	MA(250) :	18.32
MACD	MACD :	0.1	Signal :	0.1
%K %D	K(14,3) :	40.4	D(3) :	38
RSI	RSI(14): 59.4
52-week	High :	55.88	Low :	5.2

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ KRRO ] has closed above the upper band by 2.0%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 80% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 67 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	14.8 - 14.88	14.88 - 14.94
Low:	12.42 - 12.49	12.49 - 12.55
Close:	12.69 - 12.8	12.8 - 12.9

Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.

Fri, 13 Mar 2026
Korro Bio Stock Gains After Tough 2025 - New Drug Candidate, Analyst Upgrades Boost Outlook - Benzinga

Fri, 13 Mar 2026
Insider Buying: New Enterprise Associates 17, L.P. Acquires Additional Shares of Korro Bio Inc (KRRO) - GuruFocus

Thu, 12 Mar 2026
Baskett Forest buys Korro Bio (KRRO) shares worth $2.3 million - Investing.com

Thu, 12 Mar 2026
Nea 17 buys Korro Bio (KRRO) shares worth $2.3 million - Investing.com

Thu, 12 Mar 2026
Korro Bio investor buys $2.3 million in KRRO stock By Investing.com - Investing.com

Thu, 12 Mar 2026
Korro Bio (KRRO) holder adds shares, pre-funded warrants in March buy - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	9 (M)
Held by Insiders	6.01e+006 (%)
Held by Institutions	6.5 (%)
Shares Short	1,090 (K)
Shares Short P.Month	0 (K)

EPS	-8.961e+007
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	-1 %
Return on Assets (ttm)	764.8 %
Return on Equity (ttm)	-29.2 %
Qtrly Rev. Growth	7.37e+006 %
Gross Profit (p.s.)	0
Sales Per Share	-24.99
EBITDA (p.s.)	18110.2
Qtrly Earnings Growth	-9.5 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-68 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	-0.52
Price to Cash Flow	3.08

Dividend	0
Forward Dividend	1.07e+006
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.